Fresenius stock at EUR 48.00, 0.42% above Xetra close
Published on 11/02/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should know
- Fresenius is scheduled to publish its third-quarter 2026 results on November 4.
- The company raised its 2026 outlook after second-quarter revenue increased organically by 6 percent.
- Fresenius Kabi and Helios remain the group's main operating businesses.
Fresenius stock traded at EUR 48.00 on Lang & Schwarz at 07:49 CET on Monday, November 2, 2026, 0.42 percent above the Xetra close of Friday, October 30, at EUR 47.80.
The healthcare group is due to publish its third-quarter 2026 results on Wednesday, November 4. Fresenius said on its Investor Relations website that the results will be released on that date.
Quarterly report sets next focus
Fresenius enters the report after raising its 2026 outlook with its second-quarter results. Second-quarter revenue reached EUR 5.864 billion, up 6 percent organically, while EBIT increased 10 percent on a currency-adjusted basis. Core net income rose 14 percent on the same basis.
The group operates through Fresenius Kabi, which supplies medicines, infusion therapies and clinical nutrition, and Helios, its hospital business. In the second quarter, Kabi generated revenue of EUR 2.244 billion and Helios EUR 3.526 billion, before special items.
Investors are likely to focus on revenue momentum, operating profit and any update to the full-year outlook when Fresenius reports.
Broader German equities can be followed through the DAX market overview.
More news and analysis are available on Fresenius stock.
